Showing results (251-260 of 269) with videos related to

Sort By:
Pageof 27
JAMA Oncology|October 5, 2023
Heterogeneity and Utility of Pharmaceutical Company Sharing of Individual-Participant Data PackagesAshley M Hopkins, Natansh D Modi, Ahmad Y Abuhelwa, et al.
BMJ (Clinical Research Ed.)|March 20, 2024
Current safeguards, risk mitigation, and transparency measures of large language models against the generation of health disinformation: repeated cross sectional analysisBradley D Menz, Nicole M Kuderer, Stephen Bacchi, et al.
ESMO Open|May 1, 2022
Patient-reported outcomes predict survival and adverse events following anticancer treatment initiation in advanced HER2-positive breast cancerN D Modi, N O Danell, R N A Perry, et al.
Frontiers in Public Health|May 26, 2025
Generative AI's healthcare professional role creep: a cross-sectional evaluation of publicly accessible, customised health-related GPTsBianca Chu, Natansh D Modi, Bradley D Menz, et al.
The American Journal of Clinical Nutrition|March 12, 2026
NIH-FDA Nutrition Regulatory Science Workshop: Advancing Research and PolicyAndrew A Bremer, Samantha Adas, Alison G M Brown, et al.
Scientific Reports|February 6, 2026
Cardiovascular medications and treatment outcomes in multiple myeloma: insights from phase III clinical trialsAhmad Y Abuhelwa, Sara A Almansour, Humaid O Al-Shamsi, et al.
JMIR Infodemiology|April 20, 2026
Cross-Sectional Evaluation of Medical Disinformation Safeguards in Consumer-Facing Large Language Model PlatformsNatansh D Modi, Cyril A Alex, Abdulhalim A Awaty, et al.
Therapeutic Advances in Medical Oncology|September 4, 2024
Antithrombotic utilization, adverse events, and associations with treatment outcomes in multiple myeloma: pooled analysis of three clinical trialsSara A Almansour, Mohammad A Y Alqudah, Ziad Abuhelwa, et al.
Blood Advances|April 23, 2025
Statin use and survival in SLL/CLL treated with ibrutinib: Pooled analysis of four randomized controlled trialsAhmad Y Abuhelwa, Sara A Almansour, Jennifer R Brown, et al.
European Journal of Haematology|March 14, 2025
Predictive and Prognostic Significance of Patient-Reported Outcomes for Survival and Adverse Events in Daratumumab-Treated Multiple MyelomaAhmad Y Abuhelwa, Sara A Almansour, Ethan Basch, et al.
Pageof 27